Storia in 2 fonti

Stealthy startup Treeline plans a reverse merger

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

Raccontata da

endpoints.news

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Stealthy startup Treeline plans a reverse merger

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

originale

endpoints.news1 mese fa

Treeline to go public via reverse merger with Standard BioTools

Treeline Biosciences goes public via reverse merger with Standard BioTools, gaining a $900M cash runway through 2029 for its three Phase 1 oncology programs.

Leggi questa versione → originale

Timeline cronologica

lunedì 8 giugno 2026·endpoints.news
Treeline to go public via reverse merger with Standard BioTools
Treeline Biosciences goes public via reverse merger with Standard BioTools, gaining a $900M cash runway through 2029 for its three Phase 1 oncology programs.
martedì 9 giugno 2026·biopharmadive.com
Stealthy startup Treeline plans a reverse merger
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.